TCMD

Over the past six months, TCMD's stock price decreased by 16.24%. In the last month, the stock experienced a 6.46% fall and a 17.78% decrease. Year-to-date, the stock has seen a decline of 22.25%, 20.14%, or 21.21%. However, looking at the past year, the stock has shown a significant increase of 57.40%, 74.00%, 62.5%, or 62.52%. The 52-week trading range for TCMD has been between approximately $13.37 and $37.77. Key events impacting the stock include Q1 2026 financial results, which reported a 23% year-over-year revenue increase to $75.3 million, a gross margin of 76.5%, a narrowed net loss to $1.8 million, and an improved Adjusted EBITDA to $3.7 million. Q2 2026 financial results showed adjusted EPS of $0.34, exceeding analyst estimates, a 9% year-over-year revenue increase to $85.7 million driven by a 12% rise in lymphedema sales, and a 76.3% gross margin, though AffloVest revenue declined 7% due to inventory adjustments. The company raised its full-year 2026 revenue guidance to a range of $360-$366 million. Product and business developments in Q1 2026 included expanding its AI-enabled order management platform, repurchasing $1.1 million of stock, receiving FDA 510(k) clearance for its next-generation AffloVest, and acquiring LymphaTech. In July 2026, Tactile Medical entered into an exclusive U.S. distribution agreement with ElastiMed Inc for its MyoSleeve wearable compression device for VA and DoD patients. In June 2026, the company also introduced its next-generation AffloVest chest wall oscillation therapy system, and $5.3 million of stock was repurchased in Q2 2026.